The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -632,797 | -61,958 | -67,274 | -92,574 |
| Change in fair value of warrant liabilities | 295,413 | -30,743 | -14,905 | -3,889 |
| Change in fair value of related-party convertible note | -236,625 | -191 | -1,169 | 1,169 |
| Non-cash interest expense related to revenue interest liability | 8,317 | 8,634 | 9,310 | 10,019 |
| Stock-based compensation expense | 8,169 | 8,746 | 8,878 | 9,648 |
| Write-off of convertible note receivable | 7,442 | - | - | - |
| Transaction costs allocated to warrant liabilities | - | 0 | 2,063 | 104 |
| Depreciation and amortization | 4,380 | 3,865 | 3,951 | 3,880 |
| Accretion of discounts on marketable debt securities, available-for-sale | 1,526 | 1,704 | 978 | 11 |
| Loss on equity method investment | - | 14,018 | - | - |
| Realized gain on instrument-specific credit risk | 1,425 | - | - | - |
| Change in fair value of derivative liabilities | -1,108 | 1,400 | -289 | -1,931 |
| Non-cash lease expense related to operating lease right-of-use assets-Nonrelated Party | 956 | 842 | 830 | 905 |
| Non-cash lease expense related to operating lease right-of-use assets-Related Party | 741 | 720 | 698 | 678 |
| Non-cash interest items, net | 62 | 63 | 63 | 62 |
| Amortization of related-party notes discounts | - | 0 | 0 | 0 |
| Unrealized losses on equity securities | - | 0 | 1 | - |
| Impairment of intangible assets | - | 0 | - | - |
| Other | 16 | 82 | 35 | 211 |
| Accounts receivable | 700 | 10,555 | 9,890 | 5,097 |
| Inventories | 4,985 | 7,894 | 63 | -1,804 |
| Prepaid expenses and other current assets-Nonrelated Party | -1,861 | -2,335 | 5,578 | 3,939 |
| Prepaid expenses and other current assets-Related Party | 1,302 | -727 | -738 | 205 |
| Other assets | 1,052 | 16 | 324 | -1,227 |
| Accounts payable | 3,901 | 979 | -1,392 | -6,216 |
| Accrued expenses and other liabilities | 3,137 | 1,925 | 5,469 | 8,723 |
| Due to and due from related parties, net | 570 | -68 | 501 | -7 |
| Operating lease liabilities-Nonrelated Party | -992 | -929 | -912 | -992 |
| Operating lease liabilities-Related Party | -938 | -912 | -881 | -852 |
| Net cash used in operating activities | -75,359 | -70,378 | -68,907 | -79,746 |
| Purchases of marketable debt securities, available-for-sale | 139,093 | 45,626 | 180,586 | 15,061 |
| Proceeds from maturities of marketable debt securities, available-for-sale | 79,382 | 59,547 | 0 | 0 |
| Proceeds from sales of marketable debt securities, available-for-sale | 39,848 | 30,927 | 0 | 0 |
| Acquisition of a business, net of transaction costs | - | 0 | 0 | - |
| Cash paid for other equity securities | 10,000 | 0 | 0 | - |
| Purchases of property, plant and equipment | 1,776 | 903 | 741 | 1,081 |
| Software development costs | 11 | 372 | 34 | - |
| Proceeds from exercise of oberland stock option, net of commissions-Stock Purchase And Option Agreement | - | 0 | 0 | 0 |
| Net cash (used in) provided by investing activities | -31,650 | 43,573 | -181,361 | -16,142 |
| Proceeds from equity offerings, net of issuance costs | 102,227 | 0 | - | - |
| Proceeds from the ripa, net of issuance costs | 75,000 | 0 | 0 | 0 |
| Proceeds from equity offerings, net of discounts and issuance costs-Private Placement And At The Market Offerings | - | 53,744 | 173,682 | 173,136 |
| Proceeds from exercises of warrants | 53,542 | 0 | 0 | 0 |
| Net share settlement for rsus vesting | 6,994 | 590 | 151 | 322 |
| Proceeds from exercise of oberland stock option, net of commissions | 971 | - | - | - |
| Principal payments on premium financing | 868 | 1,132 | - | - |
| Proceeds from exercises of stock options-Exercise Of Stock Options | - | - | 286 | 429 |
| Proceeds from exercise of oberland stock option, net of commissions-Options Excluding Stock Purchase And Option Agreement | - | 220 | - | - |
| Proceeds from borrowings | 61 | 2,884 | - | - |
| Proceeds from equity offerings, net of discounts and issuance costs-Stock Purchase And Option Agreement | - | 0 | - | - |
| Principal payments of finance leases | 13 | 12 | 12 | 4 |
| Net cash provided by (used in) financing activities | 223,926 | 54,894 | 173,519 | 172,810 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | 122 | 5 | -56 | 76 |
| Net change in cash and cash equivalents, and restricted cash | 117,039 | 28,094 | -76,805 | 76,998 |
| Cash and cash equivalents, and restricted cash, beginning of period | 89,431 | 61,337 | 138,142 | 61,144 |
| Cash and cash equivalents, and restricted cash, end of period | 206,470 | 89,431 | 61,337 | 138,142 |
ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. (IBRX)